Dividend Calendar: Week of March 30, 2026

The week of March 30, 2026 presents income investors with a diverse array of dividend opportunities across multiple sectors. This week’s ex-dividend calendar features 15 prominent companies spanning pharmaceuticals, telecommunications, consumer goods, energy, and financial services, offering yields ranging from 2.14% to 6.07%.

Healthcare and pharmaceutical companies dominate the high-yield segment this week, with Pfizer leading at 6.07%, followed by Bristol-Myers Squibb at 5.23%. Telecommunications giants Verizon and AT&T also feature prominently, offering yields of 5.54% and 3.92% respectively.

Ex-Dividend Dates This Week

Notable High-Yield Opportunities

Income-focused investors will find particular interest in the pharmaceutical sector this week. Pfizer’s 6.07% yield stands out as the highest on the calendar, while Bristol-Myers Squibb offers a substantial 5.23% return. Verizon Communications rounds out the top three with its 5.54% yield, reflecting the telecommunications sector’s commitment to shareholder returns.

The energy sector is well-represented with Chevron offering $6.91 per share and Exxon Mobil providing $4.04 per share. These companies continue to demonstrate strong cash flow generation capabilities in the current energy environment.

Sector Diversification

This week’s dividend calendar provides excellent sector diversification opportunities. Consumer staples are represented by PepsiCo, Procter & Gamble, and Coca-Cola, offering stability and consistent dividend growth histories. The financial sector features U.S. Bancorp and Wells Fargo, both maintaining competitive yields above 2%.

Healthcare remains a cornerstone for dividend investors, with five companies on this week’s calendar including pharmaceutical giants and biotechnology firms. The sector’s defensive characteristics and steady cash flows make these dividends particularly attractive during uncertain market conditions.

How to Use a March 30 Ex-Dividend Date Calendar

The week of March 30 sits at the close of fiscal Q1 2026, a window that historically hosts a denser-than-average ex-dividend cluster as institutional managers rebalance around end-of-quarter distribution conventions. To use this calendar, anchor each entry on its ex-date relative to your broker’s settlement cycle: shares held through the ex-date capture the upcoming distribution, while shares purchased on or after the ex-date do not. With Pfizer at 6.07% and Bristol-Myers Squibb at 5.23% the entry-timing math differs sharply between the high-yield pharmaceutical pair and the consumer-staples cluster (PepsiCo 3.62%, Procter & Gamble 2.95%, Coca-Cola 2.69%, Johnson & Johnson 2.14%) where the absolute dividend-per-share is larger but the yield is materially lower.

The Mar 30 timing is also one of the last clean entry windows before fiscal Q2 begins, so income funds with March fiscal calendars often top up this week to keep their quarterly distribution yields anchored. Check your broker’s settlement-cycle rules before assuming any ex-date listed as “TBD” will coincide with the dividend declaration date — companies sometimes adjust ex-dates a day forward or backward depending on holiday calendars and exchange rules.

Sector Concentration Analysis: Pharma + Telecom Drive Q1-End Yield

The Mar 30 calendar is top-heavy in two sectors. Pharmaceuticals contribute three of the four highest yields: Pfizer (PFE) at 6.07%, Bristol-Myers Squibb (BMY) at 5.23%, plus Johnson & Johnson (JNJ) at 2.14% as a quality-comp anchor. AbbVie (ABBV) at 3.18% and Merck (MRK) at 2.75% add a second pharma pair priced at lower yields but with diversified therapeutic pipelines. Combined pharmaceutical weight on this week’s calendar is five entries, the largest sector presence. Gilead Sciences (GILD) at 2.28% rounds the healthcare group to six entries when biotech is included.

Telecommunications contributes the rest of the top tier: Verizon Communications (VZ) at 5.54% and AT&T (T) at 3.92%, both above the 3.5% threshold that dividend-growth investors typically treat as a “telecom-yield-floor.” By contrast, energy is represented by Chevron (CVX) at $6.91 per share (3.47% yield) and Exxon Mobil (XOM) at $4.04 per share (2.51%) — high absolute dollars, moderate yields, reflecting the post-2022 capital-return reset in the integrated oils. Consumer staples contribute four entries (PepsiCo at $5.69, Procter & Gamble at $4.23, Coca-Cola at $2.06, plus Johnson & Johnson which straddles healthcare) clustered between 2.14% and 3.62%. Financials are limited to U.S. Bancorp (USB) at $2.06 (3.89% yield) and Wells Fargo (WFC) at $1.80 (2.23%). Industrials are notably absent from this week’s highest tier.

Yield Tiers and Risk: 2-3% Defensive vs 5-6% Pharma

Sorting this week’s 15 entries by yield puts them in three distinct risk tiers. The top tier (5%+ yield, three entries) is pharmaceutical and telecom defensive beta — Pfizer 6.07%, Verizon 5.54%, Bristol-Myers Squibb 5.23%. AT&T 3.92% sits just below the 5% line but groups with the high-yield defensive cluster given its telecom utility-like revenue base. The middle tier (3-5%, four entries) is consumer staples and regional-bank yield: U.S. Bancorp 3.89%, PepsiCo 3.62%, Chevron 3.47%, AbbVie 3.18%. The bottom tier (2-3%, eight entries) is large-cap diversified and regulated names — Procter & Gamble 2.95%, Merck 2.75%, Coca-Cola 2.69%, Exxon Mobil 2.51%, Gilead 2.28%, Wells Fargo 2.23%, Johnson & Johnson 2.14%.

Income investors with a yield-floor mandate should think twice about treating the tiers identically. Pfizer’s 6.07% yield sits well above the pharmaceutical sector median (which is closer to 3-4%) and carries higher payout-ratio risk — a future dividend reset would represent a yield-trap risk. By contrast, Johnson & Johnson’s 2.14% is closer to the company’s long-run dividend-coverage range and signals stability rather than risk. The 5.23% from Bristol-Myers Squibb, 5.54% from Verizon, and 3.92% from AT&T can be evaluated similarly: yield above sector median generally implies payout-ratio strain or secular revenue decline, not “free” income. The mid-tier AbbVie 3.18% and U.S. Bancorp 3.89% typically pair high yield with strong cash-flow coverage from diversified business mixes and signal more durable income than the headline yield suggests.

Timing the Ex-Dividend Trade in a Q1 Volatility Window

The Mar 30 ex-dividend cluster sits at the closing week of Q1, a window that historically shows elevated realized volatility as fund managers square positions before Q2 fiscal reporting. Stocks with ex-dates in this week tend to show a small mechanical price drop on the ex-date equal to the dividend amount (e.g. Pfizer’s $1.72 per share, Chevron’s $6.91 per share) but the transaction-cost arithmetic differs by yield-tier. The high-yield entries (PFE, BMY, VZ) carry meaningful per-share dividends that can be captured with smaller position sizes, while the lower-yield entries (JNJ, KO, WFC) require larger positions to generate equivalent quarterly income — a consideration for income ETFs that want to weight by dollar-income rather than headline yield.

For investors funding tax-advantaged accounts (Japanese NISA equivalents like the Tsumitate or Growth portfolios), the timing question is mostly about entry mechanics rather than tax. For taxable accounts, the ex-date is also the last day to establish tax-basis eligibility: buying on the ex-date or later means missing the dividend AND losing the corresponding basis step-up at distribution, which can shift the optimal “buy before” / “wait until after” decision by a day or two. Brokers publish their record-date convention in the prospectus; check it before sizing any Mar 30 entry in a taxable account. The 5.23% Bristol-Myers Squibb capture alone requires the buyer to hold approximately 19.1 years of dividends to recover a single share at the current $3.12 quarterly distribution, an income horizon worth factoring against the stock’s price-volatility path through Q2.

This information is for educational purposes only and does not constitute investment advice. Dividend payments and yields are subject to change. Investors should conduct their own research and consult with financial advisors before making investment decisions. Past performance does not guarantee future results.